Xcout Intel
ECHOIQ LIMITED
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is based in Claremont, Australia.
Subscribe to see ECHOIQ LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ECHOIQ LIMITED at a glance
ECHOIQ LIMITED is a software & services company headquartered in Sydney, Australia. It is publicly listed (EIQ) with a market capitalisation of $282.8M. Xcout tracks 6 named people at ECHOIQ LIMITED, including Dustin Haines (Chief Executive Officer).
ECHOIQ LIMITED leadership
- Dustin HainesChief Executive Officer
- Nick LubbersUS President and General Manager
- Matthew DoddsChief Financial Officer
- Sam DribinChief Technology Officer
- Dane BrescacinSVP Regulatory Affairs
- Patrick O’SheaHead of Strategy & Operations
ECHOIQ LIMITED competitors
A few of ECHOIQ LIMITED's closest competitors — see the full list of competitors and alternatives →
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Voquill provides a real-time AI voice reporting software designed for pathologists. The platform automatically transcribes spoken dictation into structured, compliant pathology reports and integrates with existing laboratory information systems and templates.
AliveCor, Inc. is a privately held medical device and software company transforming cardiological care using deep learning and mobile ECG technology. It is headquartered in Mountain View, California.
NoviqTech Limited develops and delivers carbon reporting and guarantee of origin solutions in Australia and Europe. The company offers Carbon Central, a solution to centrally manage carbon projects, including carbon reporting, carbon tokenization, or guarantee of origin of green fuels and resources. It also provides NoviqAI, which offers end-to-end transparency and confirmation of product authenticity and processes throughout the entire value chain. The company was formerly known as Tymlez Group Limited and changed its name to NoviqTech Limited in October 2023. NoviqTech Limited was founded in 2016 and is based in Sydney, Australia.
Avoca Systems is an AI-powered operating system provider for radiology networks with headquarters in Darlinghurst, New South Wales, Australia.
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Get ECHOIQ LIMITED's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ECHOIQ LIMITED in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access